Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion

RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects

(2010) Haiming Sun et al.   BREAST CANCER RESEARCH AND TREATMENT

XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects

(2010) Ke-Da Yu et al.   BREAST CANCER RESEARCH AND TREATMENT

New conflicting results obtained in the subgroup analysis of RAD51 135G>C polymorphism and breast cancer risk

(2010) Pei-Hua Lu et al.   BREAST CANCER RESEARCH AND TREATMENT

XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis

(2010) Li-Xin Qiu et al.   BREAST CANCER RESEARCH AND TREATMENT

No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis

(2010) Ke-Da Yu et al.   BREAST CANCER RESEARCH AND TREATMENT

RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects

(2010) Zhanwei Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis

(2010) Guo-Wu Zhou et al.   BREAST CANCER RESEARCH AND TREATMENT

RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies

(2010) Lin-Bo Gao et al.   BREAST CANCER RESEARCH AND TREATMENT

Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis

(2009) Ke-Da Yu et al.   BREAST CANCER RESEARCH AND TREATMENT

Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects

(2009) Ke-Da Yu et al.   BREAST CANCER RESEARCH AND TREATMENT